Resources
Scientific, clinical, Medical Affairs, corporate, and educational resources supporting informed review of Breathe Biologics, the JadiCell™ platform, pulmonary disease biology, and ongoing clinical development.
Scientific Information for Medical, Research & Business Audiences
The resource center provides organized access to peer-reviewed evidence, pulmonary medical education, scientific materials, corporate information, media resources, and future expert discussions.
Published Evidence
Peer-reviewed clinical and translational publications relevant to JadiCell™ and pulmonary regenerative immunology.
Medical Affairs
Educational and scientific resources intended for healthcare, research, and professional audiences.
Corporate & Media Materials
Approved presentations, scientific materials, investor information, and media resources for external audiences.
Peer-Reviewed Clinical & Scientific Evidence
Selected publications supporting scientific review of the JadiCell™ platform and related pulmonary regenerative-medicine research.
COVID-19-Associated ARDS Clinical Study
Published randomized, double-blind, placebo-controlled Phase 1/2a study evaluating umbilical cord-derived mesenchymal stromal cells in COVID-19-associated ARDS.
Biomarker & Immunologic Analysis
Published translational analysis exploring inflammatory mediators and immunologic observations associated with investigational cell therapy in ARDS.
Pulmonary Medicine Resource Library
Scientific and disease-education resources for healthcare, research, and professional audiences.
ARDS: Pathology, Current Management & Emerging Regenerative Medicine Research
A Medical Affairs review examining ARDS pathobiology, current management approaches, and emerging areas of regenerative medicine research.
This resource is provided for scientific and educational purposes and is not intended as medical advice or promotional communication.
View ARDS Review →Scientific & Professional Inquiries
Healthcare professionals, researchers, and other qualified professional audiences may contact Breathe Biologics regarding scientific resources, publications, or Medical Affairs information.
Medical information qualification: Resources are intended for scientific, educational, and professional informational purposes. They should not be interpreted as medical advice or as establishing the safety or efficacy of JadiCell™ for any indication.
Scientific, Medical Affairs & Corporate Materials
Approved materials covering the JadiCell™ platform, clinical development, translational science, pulmonary medicine, manufacturing, intellectual property, and corporate strategy.
Breathe Biologics Corporate / Investor Presentation
September 2026 overview of Breathe Biologics, clinical development, the JadiCell™ platform, pulmonary pipeline, manufacturing and CMC, intellectual property, and strategic opportunity.
View Presentation →JadiCell™ Scientific Slide Deck
Scientific and Medical Affairs presentation covering ARDS, the JadiCell™ platform, proposed biological mechanisms, clinical evidence, and pulmonary development.
View Scientific Deck →Breathe Biologics Press-Ready Media Kit
September 2026 media resource containing company background, scientific and clinical context, frequently asked questions, editorial guidance, approved terminology, and company information.
View Media Kit →Mechanism of Action
Explore proposed pathways under investigation, including immune modulation, cytokine regulation, endothelial stabilization, epithelial repair, and tissue remodeling.
Explore Mechanism of Action →Pharmacodynamic Biomarkers
Explore translational information regarding inflammatory mediators and pharmacodynamic findings associated with published clinical research.
Explore Biomarkers →Manufacturing & Scalability
Learn about the JadiCell™ allogeneic manufacturing platform, cell banking, controlled expansion, characterization, cryopreservation, and clinical-product scalability.
Manufacturing Overview →Clinical Evidence & Trials
Review published human clinical evidence, safety information, and the ongoing clinical-development strategy for JadiCell™.
Clinical Development →Pulmonology & Critical-Care Guest Experts
This section is reserved for future educational conversations featuring pulmonologists, critical-care physicians, pulmonary researchers, and other guest experts discussing respiratory medicine, disease biology, and emerging scientific research.
Downloadable Resources
Approved scientific, Medical Affairs, corporate, investor, and media materials available for external review.
ARDS Medical Affairs Review
ARDS: Pathology, Current Management & Emerging Regenerative Medicine Research — A Medical Affairs Review.
Open ARDS Review →JadiCell™ Scientific Slide Deck
Scientific and Medical Affairs presentation covering ARDS, JadiCell™ biology, clinical evidence, and pulmonary development.
Open Scientific Deck →Corporate / Investor Presentation
September 2026 corporate overview of Breathe Biologics and its pulmonary regenerative-medicine development platform.
Open Presentation →Press-Ready Media Kit
Company background, clinical and scientific context, media FAQs, editorial guidance, approved terminology, and information for journalists and editors.
Open Media Kit →Scientific and medical information: JadiCell™ is investigational and has not been approved for the treatment, prevention, diagnosis, or cure of any disease. Resources are provided for scientific, educational, corporate, investor, or media informational purposes as applicable.